Publications by authors named "O Loutochin"
Multiparametric magnetic resonance imaging (mpMRI) has made dramatic inroads into the management of localized prostate cancer (PCa); however, not all suspicious lesions represent clinically significant (cs) PCa. We aimed to analyze the hypothetical effect of incorporating tumor volume ratio (TVR) into prostate biopsy (PBx) decision-making. Two hundred and fifty-two patients with suspicious lesions at mpMRI undergoing transperineal PBx under local anesthesia between 2019 and 2022 were retrospectively evaluated.
View Article and Find Full Text PDFArticle Synopsis
- The study compared the effectiveness of magnetic resonance imaging-guided targeted biopsy (MTBx) alone versus combining it with systematic biopsy (SBx) for detecting prostate cancer (PCa) and clinically significant PCa (csPCa) in men undergoing outpatient transperineal biopsies under local anesthesia.* -
- Out of 255 men reviewed, the detection rates for PCa were similar between MTBx (56%) and the MTBx plus SBx combination (61%), with both methods showing comparable results for csPCa, despite MTBx requiring fewer biopsy cores (6 vs. 11).* -
- Factors predicting csPCa included age, prior negative biopsies, prostate-specific antigen density, and specific imaging scores
Mycobacterium bovis BCG is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC-reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown.
View Article and Find Full Text PDFIntroduction: Partial gland ablation (PGA) using high intensity focal ultrasound (HIFU) is an alternative to active surveillance for low to intermediate risk localized prostate cancer. This pilot study assessed quality of life (QoL) outcomes during the implementation of PGA-HIFU at our institution.
Materials And Methods: We prospectively enrolled 25 men with a diagnosis of localized low/intermediate risk prostate cancer who elected to undergo PGA-HIFU in a pilot study at our institution between 2013 and 2016.